# US 2003/0206952 A1 · Extended release tiagabine formulations with reduced side-effects

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0206952 A1
- Document ID: US20030206952A1
- Status: Published application
- Kind: A1
- Application number: 10/421,043
- Filed: 2003-04-23
- Published: 2003-11-06
- Earliest claimed: 1998-01-22
- Inventors: Francisco Javier Alvarez; Kathleen M. Apfelbaum; David M. Brown; Linda E. Gustavson; Russell T. Slade
- Web page: https://patentgrep.com/patent/US20030206952A1

## CPC

- A61K 31/4535: containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A61K 9/1617: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Extended release tiagabine formulations that demonstrate fewer side-effects when administered to a patient.

## Claims

### Claim 1

An extended release formulation comprising tiagabine combined in a matrix with a hydrophilic polymer selected from the group consisting of high molecular weight polyethylene oxide and hydroxypropylmethyl cellulose.

### Claim 2 (depends on 1)

The formulation according to claim 1 wherein the hydrophilic polymer is selected from high molecular weight polyethylene oxide.

### Claim 3 (depends on 2)

The formulation according to claim 2 wherein the formulation is shaped in a tablet form.

### Claim 4 (depends on 1)

The formulation according to claim 1 wherein the hydrophilic polymer is hydroxypropylmethyl cellulose.

### Claim 5 (depends on 4)

The formulation according to claim 4 is shaped in a in a tablet form.

### Claim 6

An extended release formulation comprising tiagabine encapsulated in a formulation with a hydrophobic material selected from the group consisting of waxes, glyceryl behenate, triglycerides and mixtures thereof.

### Claim 7 (depends on 6)

The formulation according to claim 6 wherein the hydrophobic material is glyceryl behenate.

### Claim 8 (depends on 7)

The formulation according to claim 7 wherein the hydrophobic material selected from glyceryl behenate, in a capsule form in which the tiagabine is encapsulated in the formulation with glyceryl behenate by suspending the drug in the molten material and forming small spherical particles as the molten material comes into contact with a disk rotating at high speed, with subsequent cooling of the particles and subsequent formulation into capsules.

### Claim 9

An extended release formulation comprising about 0.5 to 30 wt. % tiagabine combined in a matrix having:
a. about 15 to 80 wt. % of high molecular weight polyethylene oxide;
b. about 5 to 80 wt. % of a filler selected from the group consisting of microcrystalline cellulose, starch, and sugars;
c. about 0.1 to 4 wt. % of silicon dioxide;
d. about 0.1 to 1.5 wt. % of a preservative selected from the group consisting of tocopherol, BHA and BHT;
e. about 0.1 to 6 wt. % of a first lubricant selected from the group consisting of a wax, stearic acid, mineral oil, stearate and a hydrogenated vegetable oil; and
f. about 0.05 to 1 wt. % of a second lubricant selected from the group consisting of magnesium stearate, calcium stearate and talc.

### Claim 10

An extended release formulation comprising about 0.5 to 30 wt. % tiagabine combined in a matrix having:
a. about 28 to 60 wt. % of a hydrophilic polymer selected from the group consisting of HPMC and hydroxypropyl cellulose;
b. about 5 to 80 wt. % of a filler selected from the group consisting of microcrystalline cellulose, starch, and sugars;
c. about 0.1 to 4 wt. % of silicon dioxide;
d. about 0.1 to 1.5 wt. % of a preservative selected from the group consisting of tocopherol, BHA and BHT;
e. about 0.1 to 6 wt. % of a first lubricant selected from the group consisting of a wax, stearic acid, mineral oil, stearate and a hydrogenated vegetable oil; and
f. about 0.05 to 1 wt. % of a second lubricant selected from the group consisting of magnesium stearate, calcium stearate and talc.

### Claim 11

An extended release formulation comprising about 0.5 to 30 wt. % tiagabine encapsulated in a formulation having:
a. about 50 to 99.5 wt. % of a hydrophobic ingredient selected from the group consisting of glyceryl behenate, bees wax carnauba wax, triglycerides and hydrogenated vegetable oil;
b. about 0.1 to 4 wt. % of silicon dioxide; and
d. about 0.1 to 1.5 wt. % of a preservative selected from the group consisting of tocopherol, BHA and BHT.

### Claim 12

An extended-release tiagabine formulation, comprising from about 4 to about 80 mg tiagabine or a salt thereof, said formulation providing a mean maximum plasma concentration of tiagabine from about 10 to 1000 ng/mL from a mean of about 2 to 8 hours after administration, and a mean minimum plasma concentration of tiagabine from about 1 to 700 ng/mL from a mean of about 22 to 26 hours after repeated administration every 24 hours through steady-state conditions.

### Claim 13 (depends on 12)

An extended release formulation of claim 12 comprising tiagabine combined in a matrix with a hydrophilic polymer selected from the group consisting of high molecular weight polyethylene oxide and hydroxypropylmethyl cellulose.

### Claim 14 (depends on 13)

The formulation according to claim 13 wherein the hydrophilic polymer is high molecular weight polyethylene oxide.

### Claim 15 (depends on 13)

The formulation according to claim 13 wherein the formulation is shaped in a tablet form.

### Claim 16 (depends on 13)

The formulation according to claim 13 wherein the hydrophilic polymer is hydroxypropylmethyl cellulose.

### Claim 17 (depends on 12)

An extended release formulation of claim 12 comprising tiagabine encapsulated in a formulation with a hydrophobic material selected from the group consisting of waxes, glyceryl behenate, triglycerides and mixtures thereof.

### Claim 18 (depends on 17)

The formulation according to claim 17 wherein the hydrophobic material is glyceryl behenate.

### Claim 19

An extended-release oral tiagabine tablet, comprising from about 4 to about 80 mg tiagabine or a salt thereof, said tablet providing a mean maximum plasma concentration of tiagabine from about 10 to 1000 ng/mL from a mean of about 2 to 8 hours after administration, and a mean minimum plasma concentration of tiagabine from about 1 to 700 ng/mL from a mean of about 22 to 26 hours after repeated administration every 24 hours through steady-state conditions.

### Claim 20 (depends on 19)

An extended release tablet of claim 19 comprising tiagabine combined in a matrix with a hydrophilic polymer selected from the group consisting of high molecular weight polyethylene oxide and hydroxypropylmethyl cellulose.

### Claim 21 (depends on 20)

The extended release tablet according to claim 20 wherein the hydrophilic polymer is high molecular weight polyethylene oxide.

### Claim 22 (depends on 20)

The extended release tablet according to claim 20 wherein the hydrophilic polymer is hydroxypropylmethyl cellulose.

### Claim 23 (depends on 19)

An extended release tablet of claim 19 comprising tiagabine encapsulated in a formulation with a hydrophobic material selected from the group consisting of waxes, glyceryl behenate, triglycerides and mixtures thereof.

### Claim 24 (depends on 23)

The formulation according to claim 23 wherein the hydrophobic material is glyceryl behenate.
